Generic imatinib in chronic myeloid leukemia treatment: long-term follow-up
ConclusionsResults of this study with long-term follow-up are further evidence of that the generic imatinib is at least non-inferior to the original imatinib regarding efficacy and survival both when used initially or as a subsequent replacement for original imatinib.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Lymphoma | Myeloma | Study